Abdurrahman AKYÜZ, Burhan ASLAN, Ferhat IŞIK, Murat ÇAP, İlyas KAYA, Özgür ATLI, Ümit İNCİ, Ercan TAŞTAN, Önder BİLGE, Metin OKŞUL, Mehmet Zülküf KARAHAN

The Effect of Statin Use on In-Hospital Mortality in Covid-19 Patients

Objective: Our aim in this study was to determine whether statins with anti-inflammatory and antithrombotic properties reduce in-hospital mortality in Covid-19 patients. Materials and Methods: 1752 patients hospitalized with the diagnosis of Covid-19 between September and December 2020 were retrospectively analyzed. The patients were grouped according to statin use and their characteristics were compared. The parameters associated with mortality were examined. Results: For the patients, the median age was 64 years (53-74 interquartile range [IQR]), 804 (45.9%) were over the age of 65, 903 (51.5%) were male, 167 (9.5%) were using statins, and mortality developed in 381 (21.7%) of the patients. The multivariate logistic regression model was applied using statistically significant parameters in the univariate analysis of mortality development. The group using statins was included in the regression model because it was statistically borderline significant (p=0.052). According to this model; increased age (odds ratio (OR) =1.051, 95% confidence interval (CI) 1.039-1.063, p

PDF

___

[1] Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036.
[2] Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14:1149–63. https://doi.org/1 0.1080/17476348.2020.1804365
[3] Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and metaanalysis. EClinicalMedicine. 2020;29–30:100639. https://doi. org/10.1016/j.eclinm.2020.100639
[4] Hojyo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Infamm Regen. 2020;40:37. https://doi. org/10.1186%2Fs41232-020-00146-3
[5] Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;1:1–4. https://doi.org/10.1007/s00134-020-06088-1
[6] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8. https://doi.org/10.1016/S0140- 6736(20)30937-5
[7] Abou-Ismail MY, Diamond A, Kapoor S, et al. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15. https://doi.org/10.1016/j. thromres.2020.06.029
[8] Radenkovic D, Chawla S, Pirro M, et al. Cholesterol in relation to COVID-19: should we care about it? J Clin Med. 2020;9:1909. https://doi.org/10.3390/jcm9061909
[9] Castiglione V, Chiriacò M, Emdin M, et al. Statin therapy in COVID-19 infection. Eur Hear J Cardiovasc Pharmacother. 2020. https://doi.org/10.1093/ehjcvp/pvaa042
[10] Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID19. Int J Infect Dis. 2020;96:615–7. https://doi. org/10.1016/j.ijid.2020.05.115
[11] Fedson DS. Treating infuenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99:417– 35. https://doi.org/10.1016/j.antiviral.2013.06.018
[12] Grudzinska FS, Dosanjh DP, Parekh D, et al. Statin therapy in patients with community-acquired pneumonia. Clin Med (Northfeld Il). 2017;17:403–7. https://doi.org/10.7861/ clinmedicine.17-5-403
[13] Cariou B, Goronfot T, Rimbert A, et al. Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab. 2020. https://doi.org/10.1016/j. diabet.2020.10.001
[14] Zhang XJ, Qin JJ, Cheng X, et al. Inhospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(176– 187):e4. https://doi.org/10.1016/j.cmet.2020.06.015
[15] Republic of Turkey Ministry of Health. COVID-19 (SARSCoV- 2 INFECTION) GUIDE. https://covid19.saglik.gov.tr/ TR-66299/covid-19-tedavi.html
[16] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019- nCoV) infection is suspected. 2020. https://www.who.int/ publications-detail/clinicalmanagement-of-severe-acuterespiratory- infection-when-novel-coronavirus-(ncov)- infection-is-suspected
[17] Izcovich A, Ragusa M, Sanguine V, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One. 2020 Nov 17;15(11):e0241955. https://doi.org/10.1371/journal. pone.0241955
[18] Owens AP 3rd, Mackman N. The antithrombotic effects of statins. AnnuRevMed. 2014;65:433–45. https://doi. org/10.1146/annurev-med-051812-145304
[19] Van De Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61(11):957–61.
[20] Jacobson JR, Barnard JW, Grigoryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005; 288(32–36):L1026–32.
[21] Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
[22] Terblanche M, Smith TS, Adhikari NKJ. Statins, bugs and prophylaxis: intriguing possibilities. Crit Care. 2006;10(5):168.
[23] Mehrbod P, Ideris A, Omar AR, et al. Evaluation of antiviral effect of atorvastatin on H1N1 infection in MDCK cells. Afr J Microbiol Res. 2012;6(27):5715–9. https://doi.org/10.5897/ AJMR12.1011
[24] Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205(1):13– 9.
[25] Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an antiinflammatory effect: reduction of mRNA levels for interleukin-1, interleukin6, cyclooxygenase- 2 and p22phox by regulation of peroxisome proliferatoractivated receptor (PPAR) in primary endothelial cells. Life Sci. 2000;67(8): 863–76.
[26] Mehrbod P, Zowalaty ME, Omar AR et al. Statins reduce the expression of proinflammatory cytokines in influenza A virus infected CrFK cells. Acta Virol. 2012;56(4):353–5.
[27] Rogers AJ, Guan J, Trtchounian A, et al. Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome. Crit Care Med. 2019;47(8):1089-96. https://doi.org/10.1097/ CCM.0000000000003816
[28] Butt JH, Gerds TA, Schou M, et al. Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open. 2020 Dec 4;10(12):e044421. https://doi. org/10.1136/bmjopen-2020-044421
[29] Hariyanto TI, Kurniawan A. Statin therapy did not improve the in- hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020;14:1613–5.
[30] Oh TK, Song IA, Jeon YT. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. J Pers Med. 2021 Feb 10;11(2):116. https://doi.org/10.3390/jpm11020116